<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:51:19 -0700</creation_date>
  <update_date>2013-05-27 11:34:39 -0600</update_date>
  <accession>HMDBP00699</accession>
  <secondary_accessions>
    <accession>5972</accession>
    <accession>HMDBP04888</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>S5AR 1</synonym>
    <synonym>SR type 1</synonym>
    <synonym>Steroid 5-alpha-reductase 1</synonym>
  </synonyms>
  <gene_name>SRD5A1</gene_name>
  <general_function>Involved in 3-oxo-5-alpha-steroid 4-dehydrogenase activity</general_function>
  <specific_function>Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
</specific_function>
  <pathways>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00899</accession>
      <name>Androstanedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03818</accession>
      <name>5-Androstenediol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02961</accession>
      <name>Dihydrotestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06886</accession>
      <name>7a,12a-Dihydroxy-5a-cholestan-3-one</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02197</accession>
      <name>7a,12a-Dihydroxy-cholestene-3-one</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00053</accession>
      <name>Androstenedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01984</accession>
      <name>Finasteride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02833</accession>
      <name>Testosterone sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14511</accession>
      <name>Levonorgestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15258</accession>
      <name>Dutasteride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15347</accession>
      <name>Finasteride  e</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-ch group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid dehydrogenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid dehydrogenase activity, acting on the ch-ch group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>primary metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>steroid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cytoplasm</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cell body fiber</description>
      <go_id>GO:0070852</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>myelin sheath</description>
      <go_id>GO:0043209</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>neuronal cell body</description>
      <go_id>GO:0043025</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>perinuclear region of cytoplasm</description>
      <go_id>GO:0048471</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
      <go_id>GO:0003865</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>amide binding</description>
      <go_id>GO:0033218</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cholestenone 5-alpha-reductase activity</description>
      <go_id>GO:0047751</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>NADPH binding</description>
      <go_id>GO:0070402</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>androgen biosynthetic process</description>
      <go_id>GO:0006702</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bone development</description>
      <go_id>GO:0060348</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell differentiation</description>
      <go_id>GO:0030154</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to cAMP</description>
      <go_id>GO:0071320</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to dexamethasone stimulus</description>
      <go_id>GO:0071549</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to epinephrine stimulus</description>
      <go_id>GO:0071872</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to estradiol stimulus</description>
      <go_id>GO:0071392</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to growth factor stimulus</description>
      <go_id>GO:0071363</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to insulin stimulus</description>
      <go_id>GO:0032869</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to starvation</description>
      <go_id>GO:0009267</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to testosterone stimulus</description>
      <go_id>GO:0071394</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cerebral cortex development</description>
      <go_id>GO:0021987</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>circadian sleep/wake cycle, REM sleep</description>
      <go_id>GO:0042747</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>diterpenoid metabolic process</description>
      <go_id>GO:0016101</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>female genitalia development</description>
      <go_id>GO:0030540</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hippocampus development</description>
      <go_id>GO:0021766</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hypothalamus development</description>
      <go_id>GO:0021854</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>liver development</description>
      <go_id>GO:0001889</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>male genitalia development</description>
      <go_id>GO:0030539</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>male gonad development</description>
      <go_id>GO:0008584</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>pituitary gland development</description>
      <go_id>GO:0021983</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>progesterone metabolic process</description>
      <go_id>GO:0042448</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to follicle-stimulating hormone stimulus</description>
      <go_id>GO:0032354</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to fungicide</description>
      <go_id>GO:0060992</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to growth hormone stimulus</description>
      <go_id>GO:0060416</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to muscle activity</description>
      <go_id>GO:0014850</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>serotonin metabolic process</description>
      <go_id>GO:0042428</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>sex determination</description>
      <go_id>GO:0007530</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>spinal cord development</description>
      <go_id>GO:0021510</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>thalamus development</description>
      <go_id>GO:0021794</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>urogenital system development</description>
      <go_id>GO:0001655</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Microsome membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein (Potential)</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>5</chromosome_location>
    <locus>5p15</locus>
    <gene_sequence>&gt;780 bp
ATGGCAACGGCGACGGGGGTGGCGGAGGAGCGCCTGCTGGCCGCGCTCGCCTACCTGCAG
TGCGCCGTGGGCTGCGCGGTCTTCGCGCGGAATCGTCAGACGAACTCAGTGTACGGCCGC
CACGCGCTGCCCAGCCACAGGCTCCGAGTGCCGGCGCGGGCCGCCTGGGTGGTGCAGGAG
CTGCCCTCGCTGGCCCTGCCGCTCTACCAGTACGCCAGCGAGTCCGCCCCGCGTCTCCGC
AGCGCGCCCAACTGCATCCTCCTGGCCATGTTCCTCGTCCACTACGGGCATCGGTGCTTA
ATTTACCCGTTTCTGATGCGAGGAGGAAAGCCTATGCCACTGTTGGCATGTACAATGGCG
ATTATGTTCTGTACCTGTAACGGCTATTTGCAAAGCAGATACTTGAGCCATTGTGCAGTG
TATGCTGATGACTGGGTAACAGATCCCCGTTTTCTAATAGGTTTTGGCTTGTGGTTAACA
GGCATGTTGATAAACATCCATTCAGATCATATCCTAAGGAATCTCAGAAAACCAGGAGAT
ACTGGATACAAAATACCAAGGGGAGGCTTATTTGAATACGTAACTGCAGCCAACTATTTT
GGAGAAATCATGGAGTGGTGTGGCTATGCCCTGGCCAGCTGGTCTGTCCAAGGCGCGGCT
TTTGCTTTCTTCACGTTTTGTTTTTTATCTGGTAGAGCAAAAGAGCATCATGAGTGGTAC
CTCCGGAAATTTGAAGAGTATCCAAAGTTCAGAAAAATTATAATTCCATTTTTGTTTTAA
</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>259</residue_number>
    <molecular_weight>29458.18</molecular_weight>
    <theoretical_pi>8.942</theoretical_pi>
    <pfams>
      <pfam>
        <name>Steroid_dh</name>
        <pfam_id>PF02544</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;3-oxo-5-alpha-steroid 4-dehydrogenase 1
MATATGVAEERLLAALAYLQCAVGCAVFARNRQTNSVYGRHALPSHRLRVPARAAWVVQE
LPSLALPLYQYASESAPRLRSAPNCILLAMFLVHYGHRCLIYPFLMRGGKPMPLLACTMA
IMFCTCNGYLQSRYLSHCAVYADDWVTDPRFLIGFGLWLTGMLINIHSDHILRNLRKPGD
TGYKIPRGGLFEYVTAANYFGEIMEWCGYALASWSVQGAAFAFFTFCFLSGRAKEHHEWY
LRKFEEYPKFRKIIIPFLF</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P18405</uniprot_id>
  <uniprot_name>S5A1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>M32313</genbank_gene_id>
  <genecard_id>SRD5A1</genecard_id>
  <geneatlas_id>SRD5A1</geneatlas_id>
  <hgnc_id>HGNC:11284</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Andersson S, Russell DW: Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A. 1990 May;87(10):3640-4.</reference_text>
      <pubmed_id>2339109</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jenkins EP, Hsieh CL, Milatovich A, Normington K, Berman DM, Francke U, Russell DW: Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. Genomics. 1991 Dec;11(4):1102-12.</reference_text>
      <pubmed_id>1686016</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.</reference_text>
      <pubmed_id>10931946</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Eminovic I, Liovic M, Prezelj J, Kocijancic A, Rozman D, Komel R: New steroid 5alpha-reductase type I (SRD5A1) homologous sequences on human chromosomes 6 and 8. Pflugers Arch. 2001;442(6 Suppl 1):R187-9.</reference_text>
      <pubmed_id>11678334</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Hammond GL, Rabe T, Wagner JD: Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am J Obstet Gynecol. 2001 Aug;185(2 Suppl):S24-31.</reference_text>
        <pubmed_id>11521119</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S: Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro.  Gynecol Endocrinol. 2000 Aug;14(4):223-30.</reference_text>
        <pubmed_id>11075290</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9.</reference_text>
        <pubmed_id>16818707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Rathnayake D, Sinclair R: Male androgenetic alopecia.  Expert Opin Pharmacother. 2010 Jun;11(8):1295-304.</reference_text>
        <pubmed_id>20426708</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors.  Steroids. 2010 Feb;75(2):109-53. Epub 2009 Oct 30.</reference_text>
        <pubmed_id>19879888</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12.</reference_text>
        <pubmed_id>19707263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.</reference_text>
        <pubmed_id>19543428</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders.  Drugs. 2008;68(4):463-85.</reference_text>
        <pubmed_id>18318566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer.  Eur Urol. 2009 May;55(5):1064-73. Epub 2009 Feb 5.</reference_text>
        <pubmed_id>19200641</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. Epub 2008 Dec 16.</reference_text>
        <pubmed_id>19091347</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Thigpen AE, Russell DW: Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem. 1992 Apr 25;267(12):8577-83.</reference_text>
        <pubmed_id>1314830</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Levy MA, Brandt M, Sheedy KM, Holt DA, Heaslip JI, Trill JJ, Ryan PJ, Morris RA, Garrison LM, Bergsma DJ: Cloning, expression and functional characterization of type 1 and type 2 steroid 5 alpha-reductases from Cynomolgus monkey: comparisons with human and rat isoenzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):307-19.</reference_text>
        <pubmed_id>7734398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RA Jr, et al.: 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. Biochemistry. 1994 Mar 1;33(8):2291-6.</reference_text>
        <pubmed_id>8117686</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y: Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25(2):208-13.</reference_text>
        <pubmed_id>20460827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12.</reference_text>
        <pubmed_id>19707263</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
